INDIANAPOLIS (WISH) – Eli Lilly has an ambitious seven year plan, a giant beer merger just got a little closer to reality.
Eli Lilly laid out an ambitious agenda for launching up to 20 new drugs by 2023.
During an investor presentation, the company also said it hopes to add a significant number of uses for its existing therapies in order to bolster those drugs’ market strength.
Lilly said that it would be focusing on key franchises such as diabetes, oncology, and neurodegenerative diseases like Alzheimer’s.
In more business headlines, Anheuser-Busch’s plan to sell some Sabmiller brands overseas has helped gain approval from European union regulators who have given the green light to the $107 billion merger of the two companies.
Abinbev has so far agreed to sell the Peroni and Grolsch brands to Japan’s Asahi group for $2.9 billion.
For more business headlines from Jane King at the Nasdaq, watch Daybreak Monday through Friday.